Mammoth Biosciences
Reviewed active Updated Mar 23, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Mammoth Biosciences is a biotechnology company developing in vivo gene editing therapeutics using proprietary ultracompact CRISPR systems 1. The company was founded in 2017 by Nobel laureate Jennifer Doudna, Trevor Martin, Janice Chen, and Lucas Harrington, spinning out of Doudna’s CRISPR research at UC Berkeley 2. Mammoth’s mission is “reading and writing the code of life,” focusing on discovering and engineering novel CRISPR-Cas systems for both therapeutic and diagnostic applications 1. The company is headquartered in Brisbane, California 1.
Co-founder Jennifer Doudna received the 2020 Nobel Prize in Chemistry (with Emmanuelle Charpentier) for developing the CRISPR-Cas9 method for genome editing 3. Trevor Martin, CEO, was 28 at the time of founding 4. The company’s technology centers on ultracompact CRISPR nucleases that are significantly smaller than first-generation Cas9 systems, enabling viral delivery to hard-to-reach tissues 5.
Funding History
Mammoth Biosciences has raised approximately $363 million across six funding rounds, achieving unicorn status ($1B+ valuation) with its Series D in September 2021 6 7.
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| May 2017 | Pre-Seed | Undisclosed | NFX | — 8 |
| Nov 2017 | Seed | $1.4M | — | NFX, K50 Ventures 8 |
| Jul 2018 | Series A | $23M | Mayfield | NFX, 8VC, Tim Cook, Jeff Huber 9 6 |
| Jan 2020 | Series B | $45M | Decheng Capital | Mayfield, NFX, Verily, Brook Byers 10 |
| Nov 2020 | Series C | $45M | Redmile Group, Foresite Capital | Amazon, existing investors 6 7 |
| Sep 2021 | Series D | $150M | Redmile Group | Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX, Plum Alley 7 11 |
| Apr 2024 | Corporate | $95M equity | Regeneron | — 5 |
What Investors Say
“Being good at aggregating the right people gives founders confidence to take on the world.” — James Currier, NFX, on backing the Mammoth team 4.
What Founders Say
“As a team on the front lines of discovery in CRISPR, we’ve seen firsthand the need for new tools to deliver on the therapeutic and diagnostic promise that this technology has to offer.” — Trevor Martin, CEO, on the Series B round 10.
“We’ve had a momentous year at Mammoth, which includes the maturation of our wholly-owned CRISPR platform for breakthrough therapeutic applications.” — Trevor Martin, CEO, on the Series D announcement 11.
“Mammoth is pioneering differentiated next-generation CRISPR systems, and is in a unique position to enable novel treatment options.” — Jennifer Doudna, Co-Founder, on the Series D announcement 11.
“Mammoth’s ultracompact CRISPR systems address the size constraints of viral delivery and complement Regeneron’s targeted AAV technologies.” — Trevor Martin, CEO, on the Regeneron partnership 5.
“This exciting collaboration pairs two teams with a shared commitment to translating high science into ground-breaking in vivo genetic medicines.” — Jennifer Doudna, Co-Founder, on the Regeneron partnership 5.
Sources
-
Mammoth Biosciences website, “About Us,” accessed March 2026. https://mammoth.bio/about/↩↩↩
-
Wikipedia, “Mammoth Biosciences,” accessed March 2026. https://en.wikipedia.org/wiki/Mammoth_Biosciences↩
-
WebWire, “Mammoth Biosciences Co-Founder Professor Jennifer Doudna Wins Nobel Prize in Chemistry for CRISPR Discovery,” accessed March 2026. https://www.webwire.com/ViewPressRel.asp?aId=264918↩
-
NFX, “A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D,” accessed March 2026. https://www.nfx.com/post/mammoth-pre-seed-to-biotech-unicorn↩↩
-
Regeneron Pharmaceuticals, “Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases,” April 25, 2024. https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-mammoth-biosciences-collaborate-pursue-next↩↩↩↩
-
Crunchbase, “Mammoth Biosciences Company Profile & Funding,” accessed March 2026. https://www.crunchbase.com/organization/mammoth-biosciences↩↩↩
-
TechCrunch, “Breakout ‘CRISPR platform’ company Mammoth Biosciences is officially a unicorn,” September 9, 2021. https://techcrunch.com/2021/09/09/breakout-crispr-platform-company-mammoth-biosciences-is-officially-a-unicorn/↩↩↩
-
Crunchbase, “Seed Round - Mammoth Biosciences - 2017-11-22,” accessed March 2026. https://www.crunchbase.com/funding_round/mammoth-biosciences-seed–1fe40055↩↩
-
TechCrunch, “Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine,” July 31, 2018. https://techcrunch.com/2018/07/31/mammoth-biosciences-funding-crispr-doudna/↩
-
MedCity News, “Mammoth Biosciences raises $45M Series B round for CRISPR diagnostics, therapeutics development,” January 30, 2020. https://medcitynews.com/2020/01/mammoth-biosciences-raises-45m-series-b-round-for-crispr-diagnostics-therapeutics-development/↩↩
-
Sixth Street, “Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics,” September 9, 2021. https://sixthstreet.com/investment_announce/mammoth-biosciences-raises-195-million-to-build-next-generation-crispr-products-in-therapeutics-and-diagnostics/↩↩↩